{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.37","value":"6.23"},{"groupId":"OG001","spread":"5.18","value":"10.60"},{"groupId":"OG002","spread":"5.18","value":"6.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"The change in HAM-D scores was calculated by subtracting the score at 4 weeks from the score at baseline. The HAM-D can have total scores that range from 0 to 50, with higher scores indicating greater depression. Scores over 14 are considered to be in the depressed range.","dispersionType":"Standard Deviation","groups":[{"description":"Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and placebo once daily by mouth for the second 4 weeks","id":"OG000","title":"Placebo-Placebo"},{"description":"Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and escitalopram 10 mg once daily by mouth for the second 4 weeks","id":"OG001","title":"Placebo-Escitalopram"},{"description":"Participants in this arm were randomzied to receive escitalopram 10 mg once daily by mouth for the first 4 weeks and placebo once daily by mouth for the second 4 weeks","id":"OG002","title":"Escitalopram-Placebo"}],"paramType":"MEAN","populationDescription":"Participants who had at least 1 follow up HAM-D assessment were included. Two participants died, one without a follow up assessment and one with a HAM-D at 2 weeks. For the participant who had the HAM-D at 2 weeks and then died, the last endpoint was carried forward.","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Change in Hamilton Depression Rating Scale (HAM-D) Scores","type":"PRIMARY","unitOfMeasure":"Change in HAM-D scores"}